Farxiga® (dapagliflozin), Xigduo® XR (dapagliflozin/metformin) – Expanded indication
June 12, 2024 - AstraZeneca announced the FDA approval of Farxiga (dapagliflozin) and Xigduo XR (dapagliflozin/metformin), as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.